The Perdix company has recently started conducting phase I clinical trials with the innovative compound PRX-03140; The drug will improve memory functions and has the potential of protecting the nerves and preventing further deterioration in the patients' condition
The Perdix company announced that it has recently begun conducting phase I clinical trials on the innovative compound PRX-03140, intended for the treatment of Alzheimer's disease, memory disorders and other cognitive disorders.
It should be noted that this is the second experimental drug that the company enters into clinical trials during 2004. The experimental drug was discovered using computer models of GPCR receptors and was developed through a combination of computational chemistry with medicinal chemistry.
The drug will improve memory functions and has the potential of protecting the nerves and preventing further deterioration in their condition.
Dr. Steven Donahue, Vice President of Clinical and Regulatory Affairs, said: "We believe that PRX-03140 has great potential to become an innovative treatment for disorders affecting memory and cognition. The double action mechanism - increasing the release of acetylcholine while stimulating the production of proteins that protect the nerve cells - is especially desirable for the treatment of serious diseases such as Alzheimer's disease."
Dr. Oren Becker, one of the founders of the company and its scientific director, stated that "the PRX-03140 compound is the second experimental drug that we have discovered and brought to the clinical trials stage within a period of less than two years. This proves once again the effectiveness of the company's unique drug discovery and development system."
The study is expected to include over 40 healthy volunteers. Another multi-dose study that will include healthy, elderly volunteers as well as people with mild cognitive impairments will begin in the first half of 2005.
